Activated Clotting Time and Outcomes During Percutaneous Coronary Intervention for Non–ST-Segment–Elevation Myocardial Infarction: Insights From the FUTURA/OASIS-8 Trial

Background—Activated clotting time (ACT) is widely used to guide unfractionated heparin dosing during percutaneous coronary intervention. However, its value in predicting complications is controversial in the modern era. We sought to examine the relationship between ACT and outcomes in non–ST-segment–elevation acute coronary syndrome patients. Methods and Results—In the Fondaparinux With Unfractionated Heparin During Revascularization in Acute Coronary Syndromes (FUTURA/OASIS-8) trial, 2026 patients with non–ST-segment–elevation acute coronary syndrome treated with fondaparinux 2.5 mg/d and undergoing percutaneous coronary intervention were randomized to low-dose unfractionated heparin (50 U/kg) or standard-dose unfractionated heparin (85 U/kg or 60 U/kg with glycoprotein IIb/IIIa inhibitors, with ACT guidance). No difference was shown for major bleeding and there was a trend toward a reduction in ischemic events with standard-dose unfractionated heparin. To clarify the additional value of ACT guidance, we analyzed with logistic modeling peri–percutaneous coronary intervention outcomes according to peak ACT as a linear function. A threshold effect was then investigated. No linear correlation was found between ACT and thrombotic or bleeding events. In patients not receiving planned glycoprotein IIb/IIIa inhibitors, a significant increase in rates of death, myocardial infarction, and target vessel revascularization was identified in patients with an ACT⩽300 s (4.86% versus 2.78%; adjusted odds ratio, 1.84; 95% confidence interval, 1.06–3.21; P=0.03). No threshold was found for hemorrhagic complications in patients with or without glycoprotein IIb/IIIa inhibitors. Conclusions—Non–ST-segment–elevation acute coronary syndrome patients undergoing percutaneous coronary intervention with an ACT⩽300 s are at increased risk of thrombotic complications. ACT, however, does not predict hemorrhagic complications. Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00790907.

[1]  M. Sabatine,et al.  Balancing the risk of mortality and major bleeding in the treatment of NSTEMI patients - a report from the National Cardiovascular Data Registry. , 2013, American Heart Journal.

[2]  Jane A. Linderbaum,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[3]  Harlan M Krumholz,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Circulation.

[4]  Jeroen J. Bax,et al.  2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.

[5]  T. Lauer,et al.  Kardiologische Aspekte der präoperativen Risikostratifizierung , 2011 .

[6]  Sunil V. Rao,et al.  Fondaparinux with UnfracTionated heparin dUring Revascularization in Acute coronary syndromes (FUTURA/OASIS 8): a randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes initially treated with , 2010, American heart journal.

[7]  S. Garg,et al.  Guidelines on myocardial revascularization. , 2010, European heart journal.

[8]  Sunil V. Rao,et al.  Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. , 2010, JAMA.

[9]  S. Rinfret,et al.  Impact of final activated clotting time after transradial coronary stenting with maximal antiplatelet therapy. , 2009, The American journal of cardiology.

[10]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[11]  S. Steinhubl,et al.  Relationship Between Activated Clotting Time and Ischemic or Hemorrhagic Complications: Analysis of 4 Recent Randomized Clinical Trials of Percutaneous Coronary Intervention , 2004, Circulation.

[12]  W Klein,et al.  Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). , 2004, European heart journal.

[13]  G. Levine,et al.  Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial. , 2003, Journal of the American College of Cardiology.

[14]  M. Schemper,et al.  A solution to the problem of separation in logistic regression , 2002, Statistics in medicine.

[15]  Deepak L. Bhatt,et al.  Defining the Optimal Activated Clotting Time During Percutaneous Coronary Intervention: Aggregate Results From 6 Randomized, Controlled Trials , 2001, Circulation.

[16]  C. Gaos,et al.  Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. , 1994, Journal of the American College of Cardiology.

[17]  Jeroen J. Bax,et al.  [2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)]. , 2016, Giornale italiano di cardiologia.

[18]  G. Stone,et al.  Relationship between the intensity of heparin anticoagulation and clinical outcomes in patients receiving glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction , 2013, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[19]  G. Lamas,et al.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients Wi , 2004, The Canadian journal of cardiology.

[20]  G. Helft,et al.  Defining the optimal activated clotting times during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. , 2001, Circulation.

[21]  Volkmar Falk,et al.  Guidelines on Myocardial Revascularization the Task Force on Myocardial Revascularization of the European Society of Cardiology (esc) and the European Association for Cardio-thoracic Surgery (eacts) Developed with the Special Contribution of the European Association for Percutaneous Cardiovascular I , 2022 .